Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)

Q: What does CUSIP 03836J201 represent in this 13F holders report?

CUSIP 03836J201 is the security identifier for APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in Q1 2026?

8 institutional investors reported APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 03836J201

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common stock, par value $0.001 per share
Shares outstanding: 9,144,889
Total 13F shares: 1,150,529
Share change: +593,072
Total reported value: $877,746
Price per share: $0.76
Number of holders: 8
Value change: +$448,255
Number of buys: 2
Number of sells: 3

Quarterly Holders Quick Answers

What is CUSIP 03836J201?
CUSIP 03836J201 identifies APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 03836J201:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Christian S. Schade	3/4/5	Director	— mixed-class rows	312,846 mixed-class rows	$976,345	—	28 Jul 2022	3/4/5
Laurence W. Lytton	13D/G	LYTTON LAURENCE W	9.9%	681,837	$913,662	$0	13 Nov 2025	13D/G
Scott M. Coiante	3/4/5	SVP, Chief Financial Officer	— mixed-class rows	234,265 mixed-class rows	$533,970	—	28 Jul 2022	3/4/5
Stonepine Capital Management, LLC	13D/G	—	4.3%	239,416	$418,978	-$82,213	31 Mar 2025	13D/G
Nantahala Capital Management, LLC	13D/G 13F	Company	4.5%	411,520	$386,829	$0	31 Dec 2025	13D/G 13F
AIGH Capital Management LLC	13F	Company	4.1%	370,541	$316,071	—	31 Dec 2025	13F
Marc Duey	3/4/5	Director	— mixed-class rows	282,401 mixed-class rows	$299,226	+$25,000	10 Dec 2025	3/4/5
Murchinson Ltd.	13F	Company	3.7%	340,139	$290,139	—	31 Dec 2025	13F
Oren Gilad	3/4/5	President/CEO, Director	— mixed-class rows	547,413 mixed-class rows	$258,459	+$50,009	12 Mar 2026	3/4/5
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	3%	270,000	$230,310	—	31 Dec 2025	13F
Eyal C. Attar	3/4/5	SVP, Chief Medical Officer, Director	— class O/S missing	57,392	$211,254	—	03 Jun 2022	3/4/5
Gregory Alan Korbel	3/4/5	SVP, Chief Operating Officer	— mixed-class rows	81,462 mixed-class rows	$168,445	—	28 Jul 2022	3/4/5
Sio Capital Management, LLC	13D/G	—	1.9%	112,223	$165,529	-$246,540	30 Sep 2025	13D/G
Lars B. Abrahmsen	3/4/5	SVP, Chief Scientific Officer	— mixed-class rows	143,700 mixed-class rows	$160,855	—	10 Mar 2022	3/4/5
Richard Peters	3/4/5	Director	— mixed-class rows	259,319 mixed-class rows	$105,051	+$99,999	31 Mar 2026	3/4/5
DRW Securities, LLC	13F	Company	1.3%	120,651	$102,915	—	31 Dec 2025	13F
Bernd R. Seizinger	3/4/5	Director	— mixed-class rows	54,145 mixed-class rows	$74,155	—	05 Jun 2025	3/4/5
MORGAN STANLEY	13F	Company	0.84%	77,030	$65,706	—	31 Dec 2025	13F
John P. Hamill	3/4/5	SrVP/CFO/Prin Fin & Acct Ofcr	— mixed-class rows	145,864 mixed-class rows	$50,680	+$35,897	31 Mar 2026	3/4/5
VANGUARD GROUP INC	13F	Company	0.64%	58,086	$49,548	—	31 Dec 2025	13F
Nadeem Q. Mirza	3/4/5	Chief Medical Officer	— mixed-class rows	33,650 mixed-class rows	$49,062	—	01 May 2024	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.56%	51,041	$43,538	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.51%	46,621	$39,767	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.45%	40,950	$34,935	—	31 Dec 2025	13F
Rifat Pamukcu	3/4/5	Director	— mixed-class rows	27,924 mixed-class rows	$31,676	—	05 Jun 2025	3/4/5
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.3%	27,332	$23,314	—	31 Dec 2025	13F
LPL Financial LLC	13F	Company	0.28%	26,052	$22,222	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.27%	24,304	$20,731	—	31 Dec 2025	13F
Fouad Namouni	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5
Michael Aaron Kelly	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5
John B. Henneman III	3/4/5	Director	— mixed-class rows	18,599 mixed-class rows	$16,570	—	05 Jun 2025	3/4/5
HighTower Advisors, LLC	13F	Company	0.15%	13,864	$11,826	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.09%	8,504	$7,255	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.09%	7,827	$6,676	—	31 Dec 2025	13F
Michael Grissinger	3/4/5	Director	— mixed-class rows	11,259 mixed-class rows	$4,680	—	05 Jun 2025	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.04%	3,299	$2,814	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.03%	2,461	$2,100	—	31 Dec 2025	13F
Gabriela Gruia	3/4/5	Director	— mixed-class rows	5,230 mixed-class rows	$1,692	—	05 Jun 2025	3/4/5
Jean-Pierre Bizzari	3/4/5	Director	— mixed-class rows	5,230 mixed-class rows	$1,692	—	05 Jun 2025	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.01%	577	$492	—	31 Dec 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	300	$255	—	31 Dec 2025	13F
WealthCollab, LLC	13F	Company	0%	158	$135	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	15	$13	—	31 Dec 2025	13F
Squadron Capital Management LLC	13D/G	Squadron Master Fund LP	9.9%	1,271,081	—	$0	30 Mar 2026	13D/G
Orin Hirschman	13D/G	—	9.9%	1,186,294	—	$0	31 Mar 2026	13D/G

Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2026

As of 31 Mar 2026, Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,150,529 shares. The largest 8 holders included AIGH Capital Management LLC, BNP PARIBAS FINANCIAL MARKETS, VANGUARD FIDUCIARY TRUST CO, LPL Financial LLC, VANGUARD CAPITAL MANAGEMENT LLC, HighTower Advisors, LLC, UBS Group AG, and SBI Securities Co., Ltd.. This page lists 8 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-14

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.